Dr. Nancy Phillips, MD
OB-GYN (Obstetrics & Gynecology) (Gynecology Physician)
125 Paterson St, Suite 4200
New Brunswick, NJ 08901
Who else practices at this address →
Middlesex County includes mental health (21% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecology Physician primary
NJ license 25MA05785700 · NJ license MA57857
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 91 | 65 |
| Complete ultrasound scan of pelvis | 67 | 60 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 66 | 59 |
| Established patient office or other outpatient visit, 30-39 minutes | 46 | 35 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 24 | 24 |
| Urinalysis, manual test | 23 | 16 |
| Established patient office or other outpatient visit, 10-19 minutes | 23 | 23 |
| Ultrasound of abdomen and pelvis artery and vein blood flow | 21 | 19 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 20 | 20 |
| Smear for infectious agents | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Estradiol Other prescribers in New Brunswick, NJ | 45 |
| Gabapentin Other prescribers in New Brunswick, NJ | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $2,653 in total to this clinician.
| Bayer HealthCare Pharmaceuticals Inc. | $2,568 |
|---|---|
| Novo Nordisk Inc | $85.06 |
| Compensation for services other than consulting (speaking, faculty) | $2,454 |
|---|---|
| Food and Beverage | $199 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Dec 10, 2025 | Compensation for services other than consulting (speaking, faculty) Lynkuet · Womens Health | $2,454 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $158,142 in research payments for these studies, mostly to the institutions running them.
- Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. · Active, not recruiting · NCT06417775 - M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. - A phase 3 randomized placebocontrolled observerblinded trial to evaluate the safety of a 6VALENT ospabased lyme disease vaccine VLA15 in healthy children 5 through 17 years of age
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.